Phase i/ii study with ruthenium compound nami-a and gemcitabine in patients with non-small cell lung cancer after first line therapyBackground This phase I/II study determined the maximal tolerable dose, dose limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of ruthenium compound NAMI-A in combination with gemcitabine in Non-Small Cell Lung Cancer patients after first line treatment....
Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound... Three representative medicinally relevant compounds, cisplatin, transplatin and the organometallic ruthenium compound RAPTA-C, were reacted with a pool of three proteins, ubiquitin, cytochrome c and superoxide dismutase, and the reaction products were analysed using high-resolution...
A fused donor−acceptor system based on an extended tetrathiafulvalene and a ruthenium complex of dipyridoquinoxalineAn application of the Horner−Wadsworth−Emmons reaction carried out on a ruthenium compound as the electrophilic precursor is described for the synthesis of fused donor−acceptor system 1 based on an extended tetrathiafulvalene and a ruthenium complex...
Potentialof cycloaddition reactions to generate cytotoxicmetal drugs in vitro... Toward this aim, we reportthe development of an organometallic ruthenium compound, functionalizedthrough a η6-bound arene ligand with a bicyclononynederivative, able to participate in strain-promoted cycloaddition reactionswith tetrazines....
